茶氯酸异丙嗪 | 17693-51-5

• 物质功能分类: 原料药 - 抗变态反应药 - 抗组胺药
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 中文名称: 茶氯酸异丙嗪
• 英文名称: (+/-)-dimethyl-(β-phenothiazin-10-yl-isopropyl)-amine; salt of 8-chloro-1,3-dimethyl-3,7-dihydro-purine-2,6-dione
• 英文别名: (+/-)-Dimethyl-(β-phenothiazin-10-yl-isopropyl)-amin; Salz des 8-Chlor-1,3-dimethyl-3,7-dihydro-purin-2,6-dions；Promethazine teoclate；8-chloro-1,3-dimethyl-7H-purine-2,6-dione;N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine
• CAS: 17693-51-5
• 化学式: C₇H₇ClN₄O₂*C₁₇H₂₀N₂S
• 分子量: 499.036
• InChiKey: YCXARMXCESBEDS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.85
• 重原子数：
  34
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 危险等级：
  6.1(b)
• 危险品运输编号：
  UN 3249
• 包装等级：
  III
• 危险类别：
  6.1(b)

反应信息

• 作为产物：
  描述：

  异丙嗪 、 8-氯茶碱 生成 茶氯酸异丙嗪
  参考文献：
  名称：

  BUDAI, Z.;TOTH, Z.;EGRI, J.;UDVARDY, GYULANE

  摘要：

  DOI：

文献信息

• SYSTEM FOR FLUORINATING ORGANIC COMPOUNDS
  申请人：Ritter Tobias

  公开号：US20110054175A1

  公开（公告）日：2011-03-03

  Described herein are fluorinated organic compounds and methods of making fluorinated organic compounds, for example, using palladium complexes. Also described herein are compositions and kits containing compounds and palladium complexes described herein.

  本文描述了含氟有机化合物及制备含氟有机化合物的方法，例如使用钯配合物。本文还描述了含有本文所述化合物和钯配合物的组合物和试剂盒。
• HIGH-VALENT PALLADIUM FLUORIDE COMPLEXES AND USES THEREOF
  申请人：Furuya Takeru

  公开号：US20110212936A1

  公开（公告）日：2011-09-01

  The present invention provides novel high-valent palladium fluoride complexes. The complexes typically include multi-dentate ligands that stabilize the octahedral coordination sphere of the palladium(IV) atom. These complexes are useful in fluorinating organic compounds, in particular aryl-containing compounds. The invention is particularly useful for fluorinating compounds with 19 F for PET imaging.

  本发明提供了新型高价钯氟配合物。这些配合物通常包括多齿配体，以稳定钯（IV）原子的八面体配位球。这些配合物在氟化有机化合物中特别是芳基含有化合物方面具有实用价值。本发明特别适用于氟化19F PET成像化合物。
• SUSTAINED-RELEASE TABLET
  申请人：YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.

  公开号：EP0664118A1

  公开（公告）日：1995-07-26

  A sustained-release tablet comprising a base tablet containing a water-swellable gelling agent and a pharmaceutically active ingredient dispersed homogeneously in said gelling agent, said base tablet being coated with a coating agent prepared by dissolving ethylcellulose and/or acetylcellulose in an organic solvent. This preparation is a sustained-release tablet which is capable of zero-order dissolution and applicable to any of water-soluble and difficultly soluble medicines, and can be prepared readily at a low cost.

  一种缓释片剂，包括含有水溶性胶凝剂的基片和均匀分散在所述胶凝剂中的药物活性成分，所述基片包覆有通过将乙基纤维素和/或乙酰纤维素溶解在有机溶剂中制备的包衣剂。这种制剂是一种缓释片剂，能够实现零阶溶解，适用于任何水溶性和难溶性药物，而且制备成本低廉。
• ORAL HEMOSTATIC AND WOUND-PROTECTIVE FILM
  申请人：TBM Company

  公开号：EP3381448A1

  公开（公告）日：2018-10-03

  The present disclosure relates to a film for oral hemostasis and wound protection and, more particularly, to a film for oral hemostasis and wound protection which, being stuck to a wound area in an oral cavity, delays or prevents microbleeds and controls medicinal component release. The film provided by the present disclosure is capable of including a polyol, an alcohol and a biodegradable polymer in the state of partial swelling, thereby locally absorbing blood or pus or arresting hemorrhage. Moreover, due to its high elongation ratio, the film provided by the present disclosure is capable of maintaining its adhesive force even when having blood, saliva and pus absorbed inside an oral cavity and conveniently deformed according to the shape of a seriously corrugated local area, which causes only slight foreign body sensation even after a long period of time of attachment on the local area. In addition, the film provided by the present disclosure includes the disintegrant which is dissolved and released by reacting with blood to form the microchannels that act as paths for drug release and is capable of adjusting the amount and the size of the microchannels, thereby controlling amount of drug release. The present disclosure doesn't require a patient to detach with their hand the film attached inside an oral cavity because the adhesive layer and the backing layer entirely vanish over time.

  本公开涉及一种用于口腔止血和伤口保护的薄膜，更具体地说，涉及一种用于口腔止血和伤口保护的薄膜，该薄膜贴在口腔的伤口部位，可延缓或防止微出血并控制药物成分的释放。本公开提供的薄膜能够在部分膨胀状态下包含多元醇、酒精和生物可降解聚合物，从而局部吸收血液或脓液或止血。此外，本公开所提供的薄膜由于具有较高的伸长率，即使在口腔内吸收了血液、唾液和脓液，也能保持其粘附力，并能方便地按照局部严重波纹的形状变形，即使在局部长时间粘附后，也只会产生轻微的异物感。此外，本公开提供的薄膜还包括崩解剂，崩解剂通过与血液反应溶解释放，形成微通道，作为药物释放的路径，并能够调节微通道的数量和大小，从而控制药物释放量。由于粘合剂层和背衬层会随着时间的推移而完全消失，因此本公开的产品不需要患者用手剥离附着在口腔内的薄膜。
• Methods of administering a trace amine-associated receptor 1 (TAAR1) agonist to patients having the minor allele of the single nucleotide polymorphism rs2237457
  申请人：Northwestern University

  公开号：US10098893B2

  公开（公告）日：2018-10-16

  Disclosed are methods and kits for diagnosing, prognosing, and treating patients having psychiatric disorders. The methods may include assessing whether a patient has a treatment resistant psychiatric disorder or assessing whether the patient is likely to develop a treatment resistant psychiatric disorder. The methods may include detecting genetic markers such as the single nucleotide polymorphism (SNP) in genes present in a genomic nucleic acid sample from the patient, and/or receiving, as a caregiver, the results of tests indicating whether the genetic markers are present in the genomic nucleic acid sample from the patient. The methods may include administering treatment to the patient, for example, based on the detected genetic markers, and administering treatment may include administering new antipsychotic drugs (APDs) that are trace amine-associated receptor 1 (TAAR1) agonists.

  所公开的是用于诊断、预后和治疗精神障碍患者的方法和试剂盒。这些方法可包括评估患者是否患有抗药性精神障碍，或评估患者是否有可能患上抗药性精神障碍。这些方法可包括检测患者基因组核酸样本中存在的遗传标记，如基因中的单核苷酸多态性（SNP），和/或作为护理者接收表明患者基因组核酸样本中是否存在遗传标记的检测结果。这些方法可包括对患者进行治疗，例如，根据检测到的遗传标记进行治疗，治疗可包括使用新的抗精神病药物（APDs），这些药物是痕量胺相关受体 1（TAAR1）激动剂。